Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘REGN3767’

A twist in the IO tail

This year’s ASCO meeting promises to be an interesting one, to say the least.

In this preview we take a look at the anti-LAG-3 – it’s half a decade on from when we first wrote about this target so how is the competitive landscape doing now?  In addition, the first phase 3 trial has finally read out so there is much to discuss on this front as well.

There’s also — and this is the key part — there’s a not so obvious twist in the long tail with a look at a future pathway to success in terms of how we might continue to improve performance of IO-IO therapies.

The potential answer may well turn out to be a surprising one to many who haven’t been following the field closely…

To learn more about our pre ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Where’s the next exciting IO target coming from?

Following the success of anti-CTLA4 and PD(L)1 therapies over the last five years or so, there is much time and attention being focused on addressing a key question, namely – what’s the next viable checkpoint target?

There are quite a few possibilities emerging, although to be fair, some of them will no doubt go by the wayside over the next year or two.  There has already been quite a bit of attrition since 2015/16.  Figuring out which ones will be a target versus being a useful marker is also an important aspect of new product development.

Competition is a fine thing – as long as they’re going in the direction you want to go.

For most of our ASCO coverage over the last few years we have tended to include a variety of approaches in the pre-conference Preview series that can run from a tumour type, a up and coming modality, an emerging target, and various other ways of looking at or making sense of the sea of data.

Here, we take a look at an IO target that is receiving much interest and explore what we know and where this might be headed… and ask whether the early promise is living up to the billing in practice?

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!